(Q34893972)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Francois Cotton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Charles R Guttmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chiara Zecca

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Dominik S Meier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Martina Sintzel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

David Leppert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

2 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/1471-2377-13-101

6 March 2020

exact match

0 references

cites work

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750382

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750382

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750382

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750382

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750382

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-101

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-101

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-101

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-101

Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750382

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

26 October 2018

1 reference

12 December 2020

Is natalizumab overshooting its rebound?

1 reference

12 December 2020

Natalizumab dosage suspension: are we helping or hurting?

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-13-101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23915113%20AND%20SRC:MED&resulttype=core&format=json